INTEGRITY LABS

Website

INTEGRITY LABS, INC.

7 Investors
Biotechnology Diagnostics
RESTON, VA

Integrity Laboratories, Inc. is a pioneering biotechnology company committed to revolutionizing the management of infectious diseases through high-complexity clinical diagnostics. By offering cutting-edge molecular diagnostic testing solutions, the company strives to enhance the speed and accuracy of infectious disease detection and treatment across the healthcare landscape.

Products & Team

Intercept PCR™ Platform

Molecular DiagnosticsSeed

The intercept PCR™ platform is an advanced molecular diagnostic testing solution that facilitates same-day and next-day results for complex infectious diseases. Its non-invasive methodology streamlines the diagnostic process, significantly enhancing patient care.

Value Proposition

The intercept PCR™ platform addresses the critical problem of slow antimicrobial testing by providing rapid and accurate diagnostics that enable healthcare providers to make timely treatment decisions.

Pain Points

Integrity Laboratories addresses the pain points of slow diagnosis, the inefficiency of traditional antimicrobial testing, the need for targeted therapies, and the importance of lowering overall healthcare costs.

Rapid turnaround times (STAT and next-day results)High-fidelity testing with over 99% specificityAbility to differentiate polymicrobial specimensIntegrated data and actionable analyticsSupport for antimicrobial stewardship
Industry
Other Technology
Primary business sector
Founded
2025
Year established
Location
RESTON, VA
Primary headquarters

Funding History

Total Raised:
$15.0M
E

Equity Offering

March 2025
$30.0M
Target
Progress
50%
Raised
$15.0M
Target
$30.0M
#000206138425000001